ARCT Stock Analysis: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$6.71
-0.26 (-3.73%)
▼
5d:
-8.71%
30d:
-2.61%
90d:
-19.74%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ARCT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $6.71, which is considered oversold relative to its 30-day fair value range of $6.85 to $7.43.
Technical Outlook: Technically, ARCT is in a downtrend. The price is currently testing key support at $6.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.60 (+207.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARCT is in a downtrend. The price is currently testing key support at $6.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.60 (+207.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.85 -
$7.43
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 207.0% below Wall St target ($20.60)
- CAUTION: Recommendation downgraded due to -8.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$6.85 -
$7.43
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.76
(11.3%)
Support & Resistance Levels
Support Level
$6.57
Resistance Level
$8.28
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.67
Wall Street Target
$20.60
(+207.0%)
Revenue Growth (YoY)
-93.0%
Profit Margin
-143.8%
Share & Embed Analysis
Last updated: July 13, 2026 11:32 PM ET
Data refreshes hourly during market hours. Next update: 12:32 AM
Data refreshes hourly during market hours. Next update: 12:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 45 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 51 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 61 BUY |
